4D Molecular Therapeutics Inc (FDMT)
26.38
0.00 (0.00%)
USD |
NASDAQ |
May 03, 16:00
26.36
-0.02
(-0.09%)
Pre-Market: 20:00
4D Molecular Therapeutics Revenue (TTM): 20.72M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 20.72M |
| September 30, 2023 | 21.99M |
| June 30, 2023 | 2.284M |
| March 31, 2023 | 2.207M |
| December 31, 2022 | 3.128M |
| September 30, 2022 | 1.973M |
| June 30, 2022 | 2.839M |
| March 31, 2022 | 17.26M |
| Date | Value |
|---|---|
| December 31, 2021 | 18.04M |
| September 30, 2021 | 16.97M |
| June 30, 2021 | 23.02M |
| March 31, 2021 | 12.08M |
| December 31, 2020 | 13.61M |
| September 30, 2020 | 16.62M |
| June 30, 2020 | 9.738M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
1.973M
Minimum
Sep 2022
23.02M
Maximum
Jun 2021
12.16M
Average
13.61M
Median
Dec 2020
Revenue (TTM) Benchmarks
| Catalent Inc | 4.098B |
| Cytokinetics Inc | 7.53M |
| Ionis Pharmaceuticals Inc | 787.65M |
| Vertex Pharmaceuticals Inc | 9.869B |
| Karyopharm Therapeutics Inc | 146.03M |